MetaCap

BrainsWay (BWAY) vs Cerus (CERS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cerus (CERS) has outperformed BrainsWay (BWAY) over the past year, gaining 14.2% versus a gain of 13.9%. Over five years, BWAY leads with a +130.7% price change compared with -73.5% for CERS. Cerus is the larger company by market cap ($373.6 million vs $341.3 million), about 1.1 times the size, while BrainsWay is growing revenue faster (+29.0% vs +16.1%).

On valuation, BrainsWay trades at a lower forward P/E (17.0x vs 123.3x for Cerus). BrainsWay converts more of its revenue into profit, with a net margin of 7.1% versus -6.7%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BWAY+13.90%CERS+14.20%
+137%+65%-7%
Nov 21, 20251 yearNov 20, 2026
BWAY+113.60%CERS-74.31%
+353%+125%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BWAY versus CERS key metrics
MetricBWAYCERS
Share price$8.48$1.85
Market cap$341.35M$373.62M
1-day change-2.86%-2.63%
YTD return-10.83%-10.19%
1-year return+13.90%+14.20%
5-year return+130.75%-73.50%
P/E ratio (TTM)35.33—
Forward P/E16.96123.33
EPS (TTM)$0.24$-0.04
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$41.02M$233.80M
Revenue growth (YoY)+29.04%+16.13%
Net income (latest FY)$2.92M$-15.63M
Gross margin74.56%—
Operating margin3.39%-3.71%
Net margin7.12%-6.68%
52-week high$17.40$3.47
52-week low$7.30$1.59
Distance from 52-week high-51.26%-46.69%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+127.24%+177.30%
Average volume110.35K2.12M
Shares outstanding40.25M201.95M
Employees129261
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • BrainsWay is more profitable, keeping 7.1 cents of every revenue dollar as net income versus -6.7 cents for Cerus.
  • BrainsWay grew revenue faster in its latest fiscal year (+29.04% vs +16.13%).

About BrainsWay

BWAY stock →

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally.

Health Care · Medical/Dental Instruments · 129 employees

About Cerus

CERS stock →

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety.

Health Care · Medical/Dental Instruments · 261 employees

BWAY vs CERS FAQ

Which is bigger, BrainsWay or Cerus?

Cerus (CERS) is larger, with a market capitalization of $373.62M compared with $341.35M for BrainsWay (BWAY).

Which stock has performed better over the past year, BWAY or CERS?

CERS returned +14.20% over the past 12 months, compared with +13.90% for BWAY (price return, excluding dividends). Past performance does not predict future results.

Are BrainsWay and Cerus in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons